Post
Health Canada grants CTA authorisation for QurAlis’ ALS therapy
Assessing the safety and tolerability of varying doses of QRL-201 in ALS patients is the primary objective of the trial.
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
Regenxbio concludes subject dosing in Phase I/II severe MPS I trial
Assessing the safety of RGX-111 is the primary endpoint of the trial.
BioAge Labs reports positive trial results for the treatment of muscle atrophy
The company plans to begin a Phase II trial in the prevention of ICU diaphragmatic atrophy and critical illness myopathy.
Relmada reports data from trial of REL-1017 for major depressive disorder
The RELIANCE I trial results showed that REL-1017-treated patients had a 15.1 point reduction in the MADRS.
Sitero and CRIO partner to improve patient safety in trials
The collaboration will remove the need for redundant, manual, and error-prone activities across the clinical lifecycle.
Suvoda unveils electronic clinical outcome assessments design toolkit
The toolkit is created to integrate with the Suvoda IRT and eConsent, and also address the historical inadequacies that impact eCOA.
Next on diversity: inclusion of participants with cognitive impairment in clinical trials
Clinical Trials Arena dives into a frequently forgotten aspect of clinical trial diversity: participation of people with cognitive disabilities.
China NMPA grants IND clearance for trial of Ascletis’ Covid-19 drug
ASC11 was found to have potent antiviral activity against BA.1 and BA.5 Omicron variants.
Neurocrine therapy fails to meet endpoint in epileptic encephalopathy trial
The trial evaluated NBI-827104 when given once a day up to 13 weeks in paediatric EE-CSWS patients.
Tetra Bio-Pharma reports results from trial of ARDS-003 and Favipiravir
Onternabez plays a key role in mitigating the inflammatory response in various inflammatory condition targets.